The spin stops here: Inhibition of lipoprotein-associated phospholipase A2 - A promising target but a negative initial trial?

Clinical Chemistry

Volumn 55, Issue 1, 2009, Pages 21-23

  McConnell, Joseph P ^a   Jaffe, Allan S ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; BIOCHEMICAL MARKER; DARAPLADIB; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANTIINFLAMMATORY ACTIVITY; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; ENZYME INHIBITION; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAVASCULAR ULTRASOUND; MORBIDITY; MORTALITY; PUBLISHING; REVIEW;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZALDEHYDES; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; HUMANS; OXIMES; TREATMENT FAILURE;

EID: 58149229314     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2008.118364     Document Type: Review

References (18)

1. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
2. Macphee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ, Leach CA, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 1999;338(Pt 2):479-87.
3. Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 2000;150:413-9.
4. Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, Virmani R. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006;26:2523-9.
5. McConnell JP, Hoefner DM. Lipoprotein-associated phospholipase A(2). Clin Lab Med 2006;26:679-97.
6. Garza CA, Montori VM, McConnell JP, Somers VK, Kullo IJ, Lopez-Jimenez F. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc 2007;82:159-65.
7. Oei HH, van der Meer IM, Hofman A, Stijnen T, Breteler MM, Witteman JC. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 2005;111:570-5.
8. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Chambless LE, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 2005;165:2479-84.
9. McConnell JP, Jaffe AS. Variability of lipoprotein-associated phospholipase A2 measurements. Clin Chem 2008;54:932-3.
10. Serruys PW, García-García HM, Buszman P, Erne P, Verheye S, Aschermann M, et al. Integrated Biomarker and Imaging Study-2 Investigators. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008;118:1172-82.
11. Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA 1990;263:1385-9.
12. Johnson RT, Dickersin K. Publication bias against negative results from clinical trials: three of the seven deadly sins. Nat Clin Pract Neurol 2007;3:590-1.
13. Kerr NL. HARKing: hypothesizing after the results are known. Pers Soc Psychol Rev 1998;2:196-217.
14. Jaffe AS, Katus H. Acute coronary syndrome biomarkers: the need for more adequate reporting. Circulation 2004;110:104-6.
15. Nair A, Kuban BD, Tuzcu EM, Schoenhagen P, Nissen SE, Vince DG. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 2002;106:2200-6.
16. Ohayon J, Finet G, Gharib AM, Herzka DA, Tracqui P, Heroux J, et al. Necrotic core thickness and positive arterial remodeling index: emergent biomechanical factors for evaluating the risk of plaque rupture. Am J Physiol Heart Circ Physiol 2008;295:H717-27.
17. Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000;343:1148-55.
18. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 2005;26:137-44.